HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 3, 2014, Pages 288-293

  Woody, George E ^a   Bruce, Douglas ^b   Korthuis, P Todd ^c   Chhatre, Sumedha ^a   Poole, Sabrina ^a   Hillhouse, Maureen ^d   Jacobs, Petra ^e   Sorensen, James ^f   Saxon, Andrew J ^g   Metzger, David ^a   Ling, Walter ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Buprenorphine; HIV; Methadone; Risk reduction

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHETAMINE DERIVATIVE; ASPARTATE AMINOTRANSFERASE; BLEACHING AGENT; BUPRENORPHINE PLUS NALOXONE; COCAINE; DIAMORPHINE; METHADONE; OPIATE; BUPRENORPHINE; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONCURRENT SEXUAL PARTNERSHIP; DRUG ABUSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SECONDARY ANALYSIS; SEX DIFFERENCE; SEXUAL BEHAVIOR; TREATMENT DURATION; URINALYSIS; CONTROLLED STUDY; HIV INFECTIONS; MIDDLE AGED; OPIOID-RELATED DISORDERS; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; UNSAFE SEX;

ADULT; BUPRENORPHINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; METHADONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RISK REDUCTION BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; UNSAFE SEX;

EID: 84922394197     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000165     Document Type: Article

References (46)

1. Haverkos HW. HIV/AIDS and drug abuse: epidemiology and prevention. J Addict Dis. 1998;17:91-103.
2. Hubbard RL, Marsden ME, Rachal JV, et al. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill: University of North Carolina Press; 1989.
3. Ball JC, Lange WR, Myers CP, et al. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214-226.
4. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer Verlag; 1991.
5. Hubbard RL, Craddock SG, Flynn PM, et al. Overview of one-year follow-up outcomes in the substance abuse treatment outcome study (DATOS). Psychol Addict Behav. 1997;11:261-268.
6. Gowing L, Farrell R, Bornemann R, et al. Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21:193-195.
7. Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep. 1998;113:107-115.
8. Lawrinson P, Ali R, Buavirat A. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103:1484-1492.
9. Caplehorn JR, Ross MW. Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict. 1995;30:685-698.
10. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among in- and out-of-treatment intravenous drug users: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-1056.
11. Qian HZ, Hao C, Ruan Y, et al. Impact of methadone on drug use and risky sex in China. J Subst Abuse Treat. 2008;34:391-397.
12. Wong KH, Lee SS, Lim WL, et al. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003;24:233-239.
13. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
14. Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry. 1999;156:27-33.
15. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend. 1996;42:11-20.
16. Kwiatkowski CF, Booth RE. Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. J Acquir Immune Defic Syndr. 2001;26:483-489.
17. Gossop M, Marsden J, Stewart D, et al. Reduced injection risk and sexual risk behaviors after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care. 2002;14:77-93.
18. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000;77:331-344.
19. Centers for Disease Control. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR Morb Mortal Wkly Rep. 1984;33:377-379.
20. Novick DM, Joseph H, Croxon T, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990;150:97-99.
21. Blix O, Gronbladh L. Impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: Loimer N, Schmid R, Springer A, eds. Drug Addiction and AIDS. Wien, New York: Springer-Verlag; 1991;200-205.
22. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS. 1994;8:223-231.
23. Serpelloni G, Carrieri MP, Rezza G, et al. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care. 1994;6:215-220.
24. Sorenson JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17-31.
25. Farrell M, Gowing L, Marsden J, et al. Effectiveness of drug dependent treatment in HIV prevention. Int J Drug Policy. 2005;16S: S67-S75.
26. Sullivan L, Metzger DS, Fudala PJ, et al. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150-158.
27. Berg KM, Litwin A, Li X, et al. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113:192-199.
28. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35:501-516.
29. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580.
30. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
31. Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol. 1996;16:58-67.
32. Fudala PJ, Yu E, Macfadden W, et al. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 1998;50:1-8.
33. Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis. 2005;41:891-896.
34. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35:87-92.
35. Brooner RK, Greenfield L, Schmidt CW, et al. Antisocial personality disorder and HIV infection among intravenous drug abusers. Am J Psychiatry. 1993;150:53-58.
36. Lott DC, Strain EC, Brooner RK, et al. HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate, buprenorphine, and methadone. J Subst Abuse Treat. 2006;31:187-194.
37. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128:71-76. PMC3543467.
38. Needle R, Fisher DG, Weatherby N, et al. Reliability of self-reported HIV risk behaviors of drug users. Psychol Addict Behav. 1995;9:242-250.
39. Hanbury R, Cohen M, Stimmel B. Adequacy of sexual performance in men maintained on methadone. Am J Drug Alcohol Abuse. 1977;4:13-20.
40. Crowley TJ, Simpson R. Methadone dose and human sexual behavior. Int J Addict. 1978;13:285-295.
41. Hallinan R, Byrne A, Agho K, et al. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl. 2009;32:131-139.
42. Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance treatment for opioid dependence. J Clin Endocrinol Metab. 2005;90:203-206.
43. Nosyk B, Anglin MD, Brissette S, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood). 2013;32:1462-1469.
44. Fiellin DA, O'Connor PG, Chawarski M, et al. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286:1724-1731.
45. Strang J, Manning V, Mayet S, et al. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction. 2007;102:761-770.
46. Strang J, Hall W, Hickman M, et al. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ. 2010;341:c4851. doi: 10.1136/bmj.c4851.